Novartis enhances its focus with eyecare deal


Swiss pharma major Novartis is continuing its quest to excel in a few specialist fields by licensing rights to US firm Ophthotech’s lead candidate, Fovista, for wet age-related macular degeneration (AMD). Novartis will pay $200 million (£118 million) up front, with potential regulatory and sales milestone payments adding up to over $1 billion.

Novartis will market the DNA aptamer-based drug outside of the US, and will investigate combination therapies with complementary AMD drugs it has in development. Fovista is a short length of DNA designed to bind to and inactivate platelet-derived growth factor (PDGF). It has performed well in clinical trials in combination with antibody drug Lucentis (ranibizumab), which is marketed by Novartis and binds to vascular endothelial growth factor. Blocking the action of these two growth factor proteins stops blood vessels from growing into the retina, which is the main cause of wet AMD.


Related Content

$25bn-plus trade sharpens pharma giants’ focus

25 April 2014 Business

news image

Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process

Business roundup

28 January 2010 Business

news image

Industry news, February 2010

Most Commented

US approves low acrylamide spud

25 November 2014 News and Analysis

news image

The first genetically modified potato that produces less acrylamide has been granted approval in the US

Nanostripe controversy in new twist

24 November 2014 Research

news image

Creator of striped nanoparticles insists questions over structures have already been answered and accuses critics of a 'perso...